Cite
HARVARD Citation
Schwendinger, M. et al. (2022). A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus. Journal of infectious diseases. pp. 1399-1410. [Online].